Press Releases January 8, 2025: MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013…MaaT PharmaJanuary 8, 2025
